Risk Factors for Venous Thromboembolism in Patients Undergoing Total Hip Replacement and Receiving Routine Thromboprophylaxis

Pedersen, A. B.; Sorensen, H. T.; Mehnert, F.; Overgaard, S.; Johnsen, S. P.
September 2010
Journal of Bone & Joint Surgery, American Volume;Sep2010, Vol. 92-A Issue 12, p2156
Academic Journal
Background: Data on the risk factors for venous thromboembolism among patients undergoing total hip replacement and receiving pharmacological thromboprophylaxis are limited. The purpose of this study was to examine potential patient-related risk factors for venous thromboembolism following total hip replacement in a nationwide follow-up study. Methods: Using medical databases, we identified all patients who underwent primary total hip replacement and received pharmacological thromboprophylaxis in Denmark from 1995 to 2006. The outcome measure was hospitalization with venous thromboembolism within ninety days of surgery. We considered age, sex, indication for primary total hip replacement, calendar year of surgery, and comorbidity history as potential risk factors. Results: The overall rate of hospitalization for venous thromboembolism within ninety days following a primary total hip replacement was 1.02% (686 hospitalizations after 67,469 procedures) at a median of twenty-two days. The incidence of symptomatic deep venous thrombosis and of nonfatal pulmonary embolism was 0.7% (499 of 67,469) and 0.3% (205 of 67,469), respectively. The incidence of death due to venous thromboembolism or from all causes was 0.05% (thirty-eight patients) and 1.0% (678 patients), respectively. Patients with rheumatoid arthritis had a reduced relative risk for venous thromboembolism compared with patients with primary osteoarthritis (adjusted relative risk = 0.47; 95% confidence interval, 0.25 to 0.90). Patients with a high score on the Charlson comorbidity index had an increased relative risk for venous thromboembolism compared with patients with a low score (adjusted relative risk = 1.45; 95% confidence interval, 1.02 to 2.05). Patients with a history of cardiovascular disease (relative risk = 1.40; 95% confidence interval, 1.15 to 1.70) or prior venous thromboembolism (relative risk = 8.09; 95% confidence interval, 6.07 to 10.77) had an increased risk for venous thromboembolism compared with patients without that history. Conclusions: The cumulative incidence of a venous thromboembolism within ninety days of surgery among patients with total hip replacement receiving pharmacological thromboprophylaxis was 1%. This information on the associated risk factors could be used to better anticipate the risk of venous thromboembolism for an individual patient. Level of Evidence: Prognostic Level II. See Instructions to Authors for a complete description of levels of evidence.


Related Articles

  • Incidence of infection following Total Hip Replacement surgery and its risk factors; experience at Queen Alia hospital, Jordan. Al-eyadah, Zaid // Middle East Journal of Age & Ageing;Nov2012, Vol. 9 Issue 6, p9 

    Objectives: to study the incidence of sepsis following total hip replacement surgery and its etiology Patients and methods: 120 patients undergoing total hips arthroplasty between June 2010 to June 201111. This study was conducted at one center, Queen Alia hospital in Jordan. Patients were...

  • Preventing Blood Clots after Knee Arthroscopy.  // Annals of Internal Medicine;7/15/2008, Vol. 149 Issue 2, pI40 

    The article focuses on the risks of blood clots in the veins of the legs brought by orthopedic surgical procedures like hip and knee replacements. It states that clots can travel through bloodstream and primarily the cause of blockages of arteries in the lungs. It notes that doctors provide...

  • Deep vein thrombosis after total hip and knee arthroplasty in Indian patients. Jain, V.; Dhaon, B. K.; Jaiswal, A.; Nigam, V.; Singla, J. // Postgraduate Medical Journal;Dec2004, Vol. 80 Issue 950, p729 

    Background: Deep vein thrombosis (DVT) is one of the most common complications of total hip (THA) and total knee arthroplasty (TKA). Though the reported incidence of DVT is very high, that of proximal DVT is low and that of fatal thromboembolism is very low. Hence the issue of prophylaxis for...

  • New lovv-molecular-weight heparin: Effective prophylaxis against DVT.  // Geriatrics;Jun1993, Vol. 48 Issue 6, p24 

    The article presents information about Enoxaparin injection (Lovenox), a newly approved low-molecular weight heparin. It offers an effective therapeutic option for prevention of deep vein thrombosis (DVT) in patients who undergo hip replacement surgery. Unlike other pharmacoiogic agents used for...

  • Prophylaxis, Diagnosis and Therapy of Surgery-Related Complications in Orthopedic and Trauma Surgery. Bauersachs, Rupert M.; Berger, Karin; Hankowitz, Johannes; Langenberg, Kristian; Marzi, Ingo; Neubauer, G√ľnter; Pauschert, Rolf; Ulle, Tanja; Schramm, Wolfgang // European Journal of Trauma;Apr2005, Vol. 31 Issue 2, p158 

    Background and Purpose: Selective factor Xa inhibition by the synthetic pentasaccharide fondaparinux is an efficient way of preventing venous thrombosis. Fondaparinux has been shown to reduce the incidence of venous thromboembolism (VTE) by 50% compared with the low-molecular-weight heparin...

  • Clot prevention. Dunkin, Mary Anne // Arthritis Today;Jan/Feb95, Vol. 9 Issue 1, p8 

    Presents ways of preventing blood clots in the veins for anyone undergoing hip replacement surgery as reported in a study published in the `Journal of the American Medical Association.' Interventions used in the studies that include blood-thinning drugs and compression stockings or garments that...

  • Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. Leyvraz, P.F.; Bachmann, F.; Hoek, J.; Buller, H.R.; Postel, M.; Samama, M.; Vandenbroek, M.D. // BMJ: British Medical Journal (International Edition);9/7/91, Vol. 303 Issue 6802, p543 

    Examines the effectiveness of two subcutaneous prophylactic regimens for postoperative deep vein thrombosis in patients undergoing total hip replacement in Europe. Comparison between low molecular wight heparin and unfractioned heparin; Application of prophylactic measures in hip surgery; Use...

  • Hematology.  // Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS29 

    Presents an abstract of the research manuscript `Preoperative enoxaparin is more effective than postoperative enoxaparin in the prevention of deep vein thrombosis (DVT) in patients undergoing total hip replacement (THR): A pooled analysis,' by K.A. Valentine, R.D. Hull et al from the University...

  • Rivaroxaban Better than Enoxaparin for Extended Thromboprophylaxis after Hip Arthroplasty. Ciobanu, Andrea // Maedica - a Journal of Clinical Medicine;2008, Vol. 3 Issue 2, p138 

    The article offers information on the advantage of rivaroxaban over enoxaparin in extending thromboprophylaxis after hip arthroplasty. Rivaroxaban is an oral direct inhibitor of factor Xa, with a bioavailability of 80%. The study RECORD 1 (Regulation of Coagulation in Orthopedic Surgery to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics